STOCK TITAN

[8-K] SPRUCE BIOSCIENCES, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Spruce Biosciences announced that director Bali Muralidhar, Ph.D. resigned from the board and the compensation committee, effective October 15, 2025. The company stated his departure was not due to any disagreement regarding operations, policies, or practices. This is a governance update with no operational or financial changes disclosed.

Spruce Biosciences ha annunciato che il direttore Bali Muralidhar, Ph.D. si è dimesso dal consiglio di amministrazione e dal comitato di retribuzione, con effetto dal 15 ottobre 2025. L'azienda ha dichiarato che la sua uscita non è stata causata da alcuna divergenza riguardo operazioni, politiche o pratiche. Si tratta di un aggiornamento di governance senza cambiamenti operativi o finanziari annunciati.

Spruce Biosciences anunció que el director Bali Muralidhar, Ph.D. renunció a la junta y al comité de compensación, con efecto a partir del 15 de octubre de 2025. La empresa declaró que su salida no se debió a ningún desacuerdo respecto a operaciones, políticas o prácticas. Este es un informe de gobernanza sin cambios operativos o financieros anunciados.

Spruce Biosciences은 이사 Bali Muralidhar, Ph.D.가 이사회와 보상위원회에서 사임했다고 발표했으며, 시점은 2025년 10월 15일입니다. 회사는 그의 이탈이 운영, 정책 또는 관행에 관한 어떠한 이견도 원인이 아니라고 밝혔습니다. 이는 운용이나 재무 변화가 공시되지 않은 거버넌스 업데이트입니다.

Spruce Biosciences a annoncé que le directeur Bali Muralidhar, Ph.D. a démissionné du conseil d'administration et du comité de rémunération, avec effet à partir du 15 octobre 2025. La société a déclaré que son départ n'était dû à aucun désaccord concernant les opérations, les politiques ou les pratiques. Il s'agit d'une mise à jour de gouvernance sans changements opérationnels ou financiers divulgués.

Spruce Biosciences gab bekannt, dass Direktor Bali Muralidhar, Ph.D. aus dem Vorstand und dem Vergütungsausschuss zurückgetreten ist, mit Wirkung zum 15. Oktober 2025. Das Unternehmen erklärte, dass sein Weggang nicht auf irgendeinen Dissens in Bezug auf Betrieb, Richtlinien oder Praktiken zurückzuführen sei. Dies ist ein Governance-Update ohne Offenlegung operationeller oder finanzieller Änderungen.

Spruce Biosciences أعلنت أن المدير بالـي موراليدهار، دكتوراه استقال من المجلس ومن لجنة التعويضات، اعتباراً من 15 أكتوبر 2025. وذكرت الشركة أن مغادرته لم تكن بسبب أي خلاف فيما يتعلق بالعمليات أو السياسات أو الممارسات. هذا تحديث حوكمة بلا تغييرات تشغيلية أو مالية معلنة.

Spruce Biosciences宣布董事Bali Muralidhar, Ph.D.已从董事会和薪酬委员会辞任,生效日期为2025年10月15日。公司表示他的离任并非因对运营、政策或做法存在任何分歧。这只是治理更新,未披露任何运营或财务变动。

Positive
  • None.
Negative
  • None.

Spruce Biosciences ha annunciato che il direttore Bali Muralidhar, Ph.D. si è dimesso dal consiglio di amministrazione e dal comitato di retribuzione, con effetto dal 15 ottobre 2025. L'azienda ha dichiarato che la sua uscita non è stata causata da alcuna divergenza riguardo operazioni, politiche o pratiche. Si tratta di un aggiornamento di governance senza cambiamenti operativi o finanziari annunciati.

Spruce Biosciences anunció que el director Bali Muralidhar, Ph.D. renunció a la junta y al comité de compensación, con efecto a partir del 15 de octubre de 2025. La empresa declaró que su salida no se debió a ningún desacuerdo respecto a operaciones, políticas o prácticas. Este es un informe de gobernanza sin cambios operativos o financieros anunciados.

Spruce Biosciences은 이사 Bali Muralidhar, Ph.D.가 이사회와 보상위원회에서 사임했다고 발표했으며, 시점은 2025년 10월 15일입니다. 회사는 그의 이탈이 운영, 정책 또는 관행에 관한 어떠한 이견도 원인이 아니라고 밝혔습니다. 이는 운용이나 재무 변화가 공시되지 않은 거버넌스 업데이트입니다.

Spruce Biosciences a annoncé que le directeur Bali Muralidhar, Ph.D. a démissionné du conseil d'administration et du comité de rémunération, avec effet à partir du 15 octobre 2025. La société a déclaré que son départ n'était dû à aucun désaccord concernant les opérations, les politiques ou les pratiques. Il s'agit d'une mise à jour de gouvernance sans changements opérationnels ou financiers divulgués.

Spruce Biosciences gab bekannt, dass Direktor Bali Muralidhar, Ph.D. aus dem Vorstand und dem Vergütungsausschuss zurückgetreten ist, mit Wirkung zum 15. Oktober 2025. Das Unternehmen erklärte, dass sein Weggang nicht auf irgendeinen Dissens in Bezug auf Betrieb, Richtlinien oder Praktiken zurückzuführen sei. Dies ist ein Governance-Update ohne Offenlegung operationeller oder finanzieller Änderungen.

false000168355300016835532025-10-152025-10-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2025

 

 

Spruce Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39594

81-2154263

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

611 Gateway Boulevard, Suite 740

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415-655-4168

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

SPRB

 

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Director Departure

On October 15, 2025, Bali Muralidhar, Ph.D. notified Spruce Biosciences, Inc. (the “Company”) of his resignation as a member of the Company’s board of directors (the “Board”) and as a member of the compensation committee of the Board, effective immediately. Dr. Muralidhar’s resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies, practices or otherwise.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Spruce Biosciences, Inc.

Date: October 17, 2025

By:

 /s/ Samir Gharib

Samir Gharib

President and Chief Financial Officer

 


FAQ

What did SPRB disclose in this 8-K?

Spruce Biosciences reported the resignation of director Bali Muralidhar, Ph.D., effective October 15, 2025, including his departure from the compensation committee.

Was there any disagreement related to the SPRB director’s resignation?

The company stated the resignation was not the result of any disagreement on operations, policies, practices, or other matters.

What committees did the SPRB director serve on?

He served on the compensation committee and resigned from that role concurrently with his board resignation.

When did the SPRB director’s resignation take effect?

It was effective October 15, 2025.

Does this 8-K include financial or operational changes for SPRB?

No additional operational or financial changes were disclosed; this is a governance update.

Who signed the report for SPRB?

The report was signed by Samir Gharib, President and Chief Financial Officer, dated October 17, 2025.
Spruce Biosciences, Inc.

NASDAQ:SPRB

SPRB Rankings

SPRB Latest News

SPRB Latest SEC Filings

SPRB Stock Data

88.25M
550.44k
2.32%
21.05%
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO